Background: The onset of sexual maturation at puberty is a unique developmental period from a neuroendocrine perspective in that it is characterized by enhanced FSH secretion and FSH responsiveness to exogenous GnRH (vs. LH) from the gonadotrope, yet the mechanism of these dynamics remains unclear. This study aimed to elucidate this phenomenon using a human disease model of GnRH deficiency (idiopathic hypogonadotropic hypogonadism, IHH) in which GnRH input can be experimentally controlled. Methods: 25 GnRH-deficient men were selected for study based upon their baseline testicular volumes (TV) and serum inhibin B (IB) levels to represent a spectrum of pubertal/testicular development. Subjects underwent: (i) a 12-hour overnight neuroendocrine evaluation for hormonal profiling and determination of endogenous LH secretion pattern, and (ii) a 7-day exposure to a physiologic regimen of exogenous pulsatile GnRH (25 ng/kg every 2 h). Daily measurements of serum testosterone (T) and IB levels were made and a 2-hour window of frequent blood sampling was monitored to measure LH and FSH following a single i.v. GnRH bolus (25 ng/kg). All subjects were screened for known loci underlying GnRH deficiency and the response to GnRH was tracked according to genotype. Results: Among the entire cohort, no changes were noted in serum T or IB during the 7 days, thus keeping gonadal feedback relatively constant. However, serum LH and FSH levels increased significantly (p < 0.0001) in the entire cohort. When analyzed by degree of pubertal/testicular development, men with no evidence of prior spontaneous pubertal development (TV ≤3 ml, Group I) showed sharp increases in serum FSH compared to men with some prior evidence of partial puberty (TV >3 ml, Group II, p < 0.0001). Group I exhibited a decreased LH response to GnRH on day 2 compared to day 1 (p < 0.01), which did not recover until day 5 (1–4 vs. 5–7 days, p < 0.0001). Group II displayed robust and equivalent LH responses to GnRH throughout the 7-day study. Genetic studies identified 8 mutations in 4 different loci (DAX1, KAL1, GNRHR, and FGFR1) in this cohort. Conclusions: GnRH-deficient men undergoing GnRH-induced sexual maturation display an inverse relationship between FSH responsiveness to GnRH and baseline testicular size and IB levels. This observation implies that increasing seminiferous tubule maturity represents the major constraint on FSH responsiveness to GnRH in early puberty. In contrast, LH responsiveness to GnRH correlates directly with duration of GnRH exposure. Attenuated pituitary gonadotropin responses were noted in subjects harboring DAX1 mutations, consistent with known pituitary defects.

Keywords:
GnRH, LH, FSH, Puberty, Gonadal development
1.
Boyar RM, Rosenfeld RS, Kapen S, Finkelstein JW, Roffwarg HP, Weitzman ED, Hellman L: Human puberty. Simultaneous augmented secretion of luteinizing hormone and testosterone during sleep. J Clin Invest 1974;54:609–618.
2.
Prader A: Testicular size: assessment and clinical importance. Triangle 1966;7:240–243.
3.
Nielsen CT, Skakkebaek NE, Richardson DW, Darling JA, Hunter WM, Jorgensen M, Nielsen A, Ingerslev O, Keiding N, Muller J: Onset of the release of spermatozoa (spermarche) in boys in relation to age, testicular growth, pubic hair, and height. J Clin Endocrinol Metab 1986;62:532–535.
4.
Burr IM, Sizonenko PC, Kaplan SL, Grumbach MM: Hormonal changes in puberty. I. Correlation of serum luteinizing hormone and follicle stimulating hormone with stages of puberty, testicular size, and bone age in normal boys. Pediatr Res 1970;4:25–35.
5.
Jakacki RI, Kelch RP, Sauder SE, Lloyd JS, Hopwood NJ, Marshall JC: Pulsatile secretion of luteinizing hormone in children. J Clin Endocrinol Metab 1982;55:453–458.
6.
Dunkel L, Alfthan H, Stenman UH, Selstam G, Rosberg S, Albertsson-Wikland K: Developmental changes in 24-hour profiles of luteinizing hormone and follicle-stimulating hormone from prepuberty to midstages of puberty in boys. J Clin Endocrinol Metab 1992;74:890–897.
7.
Winter JS: Analysis of clinical studies with LH-RH in children and adolescents. Am J Dis Child 1976;130:590–592.
8.
Marshall JC, Case GD, Valk TW, Corley KP, Sauder SE, Kelch RP: Selective inhibition of follicle-stimulating hormone secretion by estradiol. Mechanism for modulation of gonadotropin responses to low-dose pulses of gonadotropin-releasing hormone. J Clin Invest 1983;71:248–257.
9.
Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr: Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251–1258.
10.
Manasco PK, Umbach DM, Muly SM, Godwin DC, Negro-Vilar A, Culler MD, Underwood LE: Ontogeny of gonadotropin, testosterone, and inhibin secretion in normal boys through puberty based on overnight serial sampling. J Clin Endocrinol Metab 1995;80:2046–2052.
11.
Albertsson-Wikland K, Rosberg S, Lannering B, Dunkel L, Selstam G, Norjavaara E: Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semilongitudinal study throughout puberty in healthy boys. J Clin Endocrinol Metab 1997;82:541–549.
12.
Seminara SB, Hayes FJ, Crowley WF Jr: Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann’s syndrome): pathophysiological and genetic considerations. Endocr Rev 1998;19:521–539.
13.
Hoffman AR, Crowley WF Jr: Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982;307:1237–1241.
14.
Spratt DI, Finkelstein JS, O’Dea LS, Badger TM, Rao PN, Campbell JD, Crowley WF Jr: Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism. A model for studies of the hormone’s physiologic effects. Ann Intern Med 1986;105:848–855.
15.
Crowley WF Jr, Whitcomb RW, Jameson JL, Weiss J, Finkelstein JS, O’Dea LS: Neuroendocrine control of human reproduction in the male. Recent Prog Horm Res 1991;47:27–67.
16.
Spratt DI, O’Dea LS, Schoenfeld D, Butler J, Rao PN, Crowley WF Jr: Neuroendocrine-gonadal axis in men: frequent sampling of LH, FSH, and testosterone. Am J Physiol 1988;254:E658–E666.
17.
Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr: Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:4128–4136.
18.
Doty RL, Applebaum S, Zusho H, Settle RG: Sex differences in odor identification ability: a cross-cultural analysis. Neuropsychologia 1985;23:667–672.
19.
De Roux N, Young J, Misrahi M, Genet R, Chanson P, Schaison G, Milgrom E: A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997;337:1597–1602.
20.
Oliveira LM, Seminara SB, Beranova M, Hayes FJ, Valkenburgh SB, Schipani E, Costa EM, Latronico AC, Crowley WF Jr, Vallejo M: The importance of autosomal genes in Kallmann syndrome: genotype-phenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001;86:1532–1538.
21.
Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, Bo-Abbas Y, Kuohung W, Schwinof KM, Hendrick AG, Zahn D, Dixon J, Kaiser UB, Slaugenhaupt SA, Gusella JF, O’Rahilly S, Carlton MB, Crowley WF Jr, Aparicio SA, Colledge WH: The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349:1614–1627.
22.
Achermann JC, Gu WX, Kotlar TJ, Meeks JJ, Sabacan LP, Seminara SB, Habiby RL, Hindmarsh PC, Bick DP, Sherins RJ, Crowley WF Jr, Layman LC, Jameson JL: Mutational analysis of DAX1 in patients with hypogonadotropic hypogonadism or pubertal delay. J Clin Endocrinol Metab 1999;84:4497–4500.
23.
Pitteloud N, Acierno JS Jr, Meysing AU, Dwyer AA, Hayes FJ, Crowley WF Jr: Reversible Kallmann syndrome, delayed puberty, and isolated anosmia occurring in a single family with a mutation in the fibroblast growth factor receptor 1 gene. J Clin Endocrinol Metab 2005;90:1317–1322.
24.
Yoshiura K, Leysens NJ, Chang J, Ward D, Murray JC, Muenke M: Genomic structure, sequence, and mapping of human FGF8 with no evidence for its role in craniosynostosis/limb defect syndromes. Am J Med Genet 1997;72:354–362.
25.
Pitteloud N, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, Plummer L, Jacobson-Dickman EE, Mellon PL, Zhou QY, Crowley WF Jr: Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 2007;104:17447–17452.
26.
Pitteloud N, Hayes FJ, Boepple PA, DeCruz S, Seminara SB, MacLaughlin DT, Crowley WF Jr: The role of prior pubertal development, biochemical markers of testicular maturation, and genetics in elucidating the phenotypic heterogeneity of idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2002;87:152–160.
27.
Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA, Cole LW, Pearce SH, Lee H, Boepple P, Crowley WF Jr, Pitteloud N: Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 2007;357:863–873.
28.
Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998;11:1–3.
29.
Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP, McNeilly AS: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401–1405.
30.
Hayes FJ, McNicholl DJ, Schoenfeld D, Marsh EE, Hall JE: Free α-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. J Clin Endocrinol Metab 1999;1999:1028–1036.
31.
Santen RJ, Bardin CW: Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest 1973;52:2617–2628.
32.
Pitteloud N, Meysing A, Quinton R, Acierno JS Jr, Dwyer AA, Plummer L, Fliers E, Boepple P, Hayes F, Seminara S, Hughes VA, Ma J, Bouloux P, Mohammadi M, Crowley WF Jr: Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol Cell Endocrinol 2006;254–255:60–69.
33.
Seminara SB, Achermann JC, Genel M, Jameson JL, Crowley WF Jr: X-linked adrenal hypoplasia congenita: a mutation in DAX1 expands the phenotypic spectrum in males and females. J Clin Endocrinol Metabol 1999;84:4501–4509.
34.
Habiby RL, Boepple P, Nachtigall L, Sluss PM, Crowley WF Jr, Jameson JL: Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalmic and pituitary defects in gonadotropin production. J Clin Invest 1996;98:1055–1062.
35.
Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, Hayes FJ: The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 2001;86:2470–2475.
36.
Valk TW, Corley KP, Kelch RP, Marshall JC: Pulsatile gonadotropin-releasing hormone in gonadotropin-deficient and normal men: suppression of follicle-stimulating hormone responses by testosterone. J Clin Endocrinol Metab 1981;53:184–191.
37.
Stuenkel CA, Dudley RE, Yen SS: Sublingual administration of testosterone-hydroxypropyl-β-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal men. J Clin Endocrinol Metab 1991;72:1054–1059.
38.
Miller C, Ulloa-Aguirre A, Hyland L, Chappel S: Pituitary follicle-stimulating hormone heterogeneity: assessment of biologic activities of each follicle-stimulating hormone form. Fertil Steril 1983;40:242–247.
39.
O’Connor AE, De Kretser DM: Inhibins in normal male physiology. Semin Reprod Med 2004;22:177–185.
40.
Andersson AM, Juul A, Petersen JH, Muller J, Groome NP, Skakkebaek NE: Serum inhibin B in healthy pubertal and adolescent boys: relation to age, stage of puberty, and follicle-stimulating hormone, luteinizing hormone, testosterone, and estradiol levels. J Clin Endocrinol Metab 1997;82:3976–3981.
41.
Illingworth PJ, Groome NP, Byrd W, Rainey WE, McNeilly AS, Mather JP, Bremner WJ: Inhibin-B: a likely candidate for the physiologically important form of inhibin in men. J Clin Endocrinol Metab 1996;81:1321–1325.
42.
Rivier C, Cajander S, Vaughan J, Hsueh AJ, Vale W: Age-dependent changes in physiological action, content, and immunostaining of inhibin in male rats. Endocrinology 1988;123:120–126.
43.
Anawalt BD, Bebb RA, Matsumoto AM, Groome NP, Illingworth PJ, McNeilly AS, Bremner WJ: Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction. J Clin Endocrinol Metab 1996;81:3341–3345.
44.
Lambert-Messerlian GM, Hall JE, Sluss PM, Taylor AE, Martin KA, Groome NP, Crowley WF Jr, Schneyer AL: Relatively low levels of dimeric inhibin circulate in men and women with polycystic ovarian syndrome using a specific two-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 1994;79:45–50.
45.
Kovacs K, Sheehan HL: Pituitary changes in Kallmann’s syndrome: a histologic, immunocytologic, ultrastructural, and immunoelectron microscopic study. Fertil Steril 1982;37:83–89.
46.
Bédécarrats GY, Kaiser UB: Differential regulation of gonadotropin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone in perifused L β T2 cells: role of GnRH receptor concentration. Endocrinology 2003;144:1802–1811.
47.
Pierik FH, Vreeburg JT, Stijnen T, De Jong FH, Weber RF: Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab 1998;83:3110–3114.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.